- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Adaptimmune Therapeutics is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.60 – an increase of 4.28% over the previous week. Adaptimmune Therapeutics employs 449 staff and has a trailing 12-month revenue of around $141.5 million.
What's in this guide?
Our top picks for where to buy Adaptimmune Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Adaptimmune Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ADAP. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Adaptimmune Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Adaptimmune Therapeutics stock price (NASDAQ: ADAP)
Use our graph to track the performance of ADAP stocks over time.Adaptimmune Therapeutics shares at a glance
Information last updated 2024-12-19.
| Latest market close | $0.60 |
|---|---|
| 52-week range | $0.47 - $2.05 |
| 50-day moving average | $0.74 |
| 200-day moving average | $1.05 |
| Wall St. target price | $2.27 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.17 |
Is it a good time to buy Adaptimmune Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Adaptimmune Therapeutics price performance over time
Historical closes compared with the close of $0.6049 from 2024-12-20
| 1 week (2024-12-13) | 4.28% |
|---|---|
| 1 month (2024-11-22) | -8.57% |
| 3 months (2024-09-20) | -39.27% |
| 6 months (2024-06-21) | -32.03% |
| 1 year (2023-12-21) | 27.97% |
|---|---|
| 2 years (2022-12-21) | -57.40% |
| 3 years (2021-12-21) | 4.01 |
| 5 years (2019-12-20) | 1.31 |
Is Adaptimmune Therapeutics stock undervalued or overvalued?
Valuing Adaptimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptimmune Therapeutics's PEG ratio
Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Adaptimmune Therapeutics financials
| Revenue TTM | $141.5 million |
|---|---|
| Operating margin TTM | 53.58% |
| Gross profit TTM | $-100,578,000 |
| Return on assets TTM | -15.84% |
| Return on equity TTM | -65.04% |
| Profit margin | -51.25% |
| Book value | $0.17 |
| Market Capitalization | $155.1 million |
TTM: trailing 12 months
Adaptimmune Therapeutics share dividends
We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months.
Adaptimmune Therapeutics share price volatility
Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $0.472 up to $2.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 2.247. This would suggest that Adaptimmune Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Adaptimmune Therapeutics overview
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc. ; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Frequently asked questions
nullWhat percentage of Adaptimmune Therapeutics is owned by insiders or institutions?
Currently 0.376% of Adaptimmune Therapeutics shares are held by insiders and 60.266% by institutions. How many people work for Adaptimmune Therapeutics?
Latest data suggests 449 work at Adaptimmune Therapeutics. When does the fiscal year end for Adaptimmune Therapeutics?
Adaptimmune Therapeutics's fiscal year ends in December. Where is Adaptimmune Therapeutics based?
Adaptimmune Therapeutics's address is: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX What is Adaptimmune Therapeutics's ISIN number?
Adaptimmune Therapeutics's international securities identification number is: US00653A1079 What is Adaptimmune Therapeutics's CUSIP number?
Adaptimmune Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00653A107
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question